Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: Short-term efficacy and adverse effects

Harold A. Sackeim, Elaine M. Dillingham, Joan Prudic, Thomas Cooper, W. Vaughn McCall, Peter Rosenquist, Keith Isenberg, Keith Garcia, Benoit H. Mulsant, Roger F. Haskett

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

Context: Medication resistance is the leading indication for use of electroconvulsive therapy (ECT) in major depression. The practice of stopping antidepressant medications prior to ECT derived from studies in the 1960s and 1970s in nonresistant samples. There is also continuing controversy regarding the relative efficacy and adverse effects of right unilateral and bilateral ECT. Objective: To test the hypotheses that, compared with placebo, concomitant treatment with nortriptline or venlafaxine during the ECT course enhances short-term efficacy without a meaningful effect on adverse effects and reduces the rate of post-ECT relapse, and to test the hypotheses that high-dose, right-sided, unilateral ECT is equivalent in efficacy to moderate-dosage bilateral ECT and retains advantages with respect to cognitive adverse effects. Design: Prospective, randomized, triple-masked, placebo-controlled study conducted from 2001 through 2005. Setting: Three university-based hospitals. Patients: Of approximately 750 consecutive patients referred for ECT, 319 with a major depressive episode consented, consented, were randomized to pharmacological or ECT treatment conditions, and received at least 1 ECT treatment. Main Outcome Measures: Scores on the Hamilton Rating Scale for Depression, remission rate following completion of ECT, and selective measures of cognitive adverse effects. Results: Treatment with nortriptyline enhanced the efficacy and reduced the cognitive adverse effects of ECT relative to placebo. Venlafaxine resulted in a weaker degree of improvement and tended to worsen cognitive adverse effects. High-dosage right unilateral ECT did not differ or was superior to bilateral ECT in efficacy and resulted in less severe amnesia. Conclusions: The efficacy of ECT is substantially increased by the addition of an antidepressant medication, but such medications may differ in whether they reduce or increase cognitive adverse effects. High-dose, right-sided, unilateral ECT is at least equivalent to moderate-dosage bilateral ECT in efficacy, but retains advantages with respect to cognitive adverse effects.

Original languageEnglish (US)
Pages (from-to)729-737
Number of pages9
JournalArchives of General Psychiatry
Volume66
Issue number7
DOIs
StatePublished - Jul 1 2009

Fingerprint

Electroconvulsive Therapy
Drug Therapy
Placebos
Antidepressive Agents
Depression
Nortriptyline
Amnesia
Therapeutics

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Cite this

Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes : Short-term efficacy and adverse effects. / Sackeim, Harold A.; Dillingham, Elaine M.; Prudic, Joan; Cooper, Thomas; McCall, W. Vaughn; Rosenquist, Peter; Isenberg, Keith; Garcia, Keith; Mulsant, Benoit H.; Haskett, Roger F.

In: Archives of General Psychiatry, Vol. 66, No. 7, 01.07.2009, p. 729-737.

Research output: Contribution to journalArticle

Sackeim, Harold A. ; Dillingham, Elaine M. ; Prudic, Joan ; Cooper, Thomas ; McCall, W. Vaughn ; Rosenquist, Peter ; Isenberg, Keith ; Garcia, Keith ; Mulsant, Benoit H. ; Haskett, Roger F. / Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes : Short-term efficacy and adverse effects. In: Archives of General Psychiatry. 2009 ; Vol. 66, No. 7. pp. 729-737.
@article{e9a6eb2f569047cc81a112da4b2054c3,
title = "Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: Short-term efficacy and adverse effects",
abstract = "Context: Medication resistance is the leading indication for use of electroconvulsive therapy (ECT) in major depression. The practice of stopping antidepressant medications prior to ECT derived from studies in the 1960s and 1970s in nonresistant samples. There is also continuing controversy regarding the relative efficacy and adverse effects of right unilateral and bilateral ECT. Objective: To test the hypotheses that, compared with placebo, concomitant treatment with nortriptline or venlafaxine during the ECT course enhances short-term efficacy without a meaningful effect on adverse effects and reduces the rate of post-ECT relapse, and to test the hypotheses that high-dose, right-sided, unilateral ECT is equivalent in efficacy to moderate-dosage bilateral ECT and retains advantages with respect to cognitive adverse effects. Design: Prospective, randomized, triple-masked, placebo-controlled study conducted from 2001 through 2005. Setting: Three university-based hospitals. Patients: Of approximately 750 consecutive patients referred for ECT, 319 with a major depressive episode consented, consented, were randomized to pharmacological or ECT treatment conditions, and received at least 1 ECT treatment. Main Outcome Measures: Scores on the Hamilton Rating Scale for Depression, remission rate following completion of ECT, and selective measures of cognitive adverse effects. Results: Treatment with nortriptyline enhanced the efficacy and reduced the cognitive adverse effects of ECT relative to placebo. Venlafaxine resulted in a weaker degree of improvement and tended to worsen cognitive adverse effects. High-dosage right unilateral ECT did not differ or was superior to bilateral ECT in efficacy and resulted in less severe amnesia. Conclusions: The efficacy of ECT is substantially increased by the addition of an antidepressant medication, but such medications may differ in whether they reduce or increase cognitive adverse effects. High-dose, right-sided, unilateral ECT is at least equivalent to moderate-dosage bilateral ECT in efficacy, but retains advantages with respect to cognitive adverse effects.",
author = "Sackeim, {Harold A.} and Dillingham, {Elaine M.} and Joan Prudic and Thomas Cooper and McCall, {W. Vaughn} and Peter Rosenquist and Keith Isenberg and Keith Garcia and Mulsant, {Benoit H.} and Haskett, {Roger F.}",
year = "2009",
month = "7",
day = "1",
doi = "10.1001/archgenpsychiatry.2009.75",
language = "English (US)",
volume = "66",
pages = "729--737",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "7",

}

TY - JOUR

T1 - Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes

T2 - Short-term efficacy and adverse effects

AU - Sackeim, Harold A.

AU - Dillingham, Elaine M.

AU - Prudic, Joan

AU - Cooper, Thomas

AU - McCall, W. Vaughn

AU - Rosenquist, Peter

AU - Isenberg, Keith

AU - Garcia, Keith

AU - Mulsant, Benoit H.

AU - Haskett, Roger F.

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Context: Medication resistance is the leading indication for use of electroconvulsive therapy (ECT) in major depression. The practice of stopping antidepressant medications prior to ECT derived from studies in the 1960s and 1970s in nonresistant samples. There is also continuing controversy regarding the relative efficacy and adverse effects of right unilateral and bilateral ECT. Objective: To test the hypotheses that, compared with placebo, concomitant treatment with nortriptline or venlafaxine during the ECT course enhances short-term efficacy without a meaningful effect on adverse effects and reduces the rate of post-ECT relapse, and to test the hypotheses that high-dose, right-sided, unilateral ECT is equivalent in efficacy to moderate-dosage bilateral ECT and retains advantages with respect to cognitive adverse effects. Design: Prospective, randomized, triple-masked, placebo-controlled study conducted from 2001 through 2005. Setting: Three university-based hospitals. Patients: Of approximately 750 consecutive patients referred for ECT, 319 with a major depressive episode consented, consented, were randomized to pharmacological or ECT treatment conditions, and received at least 1 ECT treatment. Main Outcome Measures: Scores on the Hamilton Rating Scale for Depression, remission rate following completion of ECT, and selective measures of cognitive adverse effects. Results: Treatment with nortriptyline enhanced the efficacy and reduced the cognitive adverse effects of ECT relative to placebo. Venlafaxine resulted in a weaker degree of improvement and tended to worsen cognitive adverse effects. High-dosage right unilateral ECT did not differ or was superior to bilateral ECT in efficacy and resulted in less severe amnesia. Conclusions: The efficacy of ECT is substantially increased by the addition of an antidepressant medication, but such medications may differ in whether they reduce or increase cognitive adverse effects. High-dose, right-sided, unilateral ECT is at least equivalent to moderate-dosage bilateral ECT in efficacy, but retains advantages with respect to cognitive adverse effects.

AB - Context: Medication resistance is the leading indication for use of electroconvulsive therapy (ECT) in major depression. The practice of stopping antidepressant medications prior to ECT derived from studies in the 1960s and 1970s in nonresistant samples. There is also continuing controversy regarding the relative efficacy and adverse effects of right unilateral and bilateral ECT. Objective: To test the hypotheses that, compared with placebo, concomitant treatment with nortriptline or venlafaxine during the ECT course enhances short-term efficacy without a meaningful effect on adverse effects and reduces the rate of post-ECT relapse, and to test the hypotheses that high-dose, right-sided, unilateral ECT is equivalent in efficacy to moderate-dosage bilateral ECT and retains advantages with respect to cognitive adverse effects. Design: Prospective, randomized, triple-masked, placebo-controlled study conducted from 2001 through 2005. Setting: Three university-based hospitals. Patients: Of approximately 750 consecutive patients referred for ECT, 319 with a major depressive episode consented, consented, were randomized to pharmacological or ECT treatment conditions, and received at least 1 ECT treatment. Main Outcome Measures: Scores on the Hamilton Rating Scale for Depression, remission rate following completion of ECT, and selective measures of cognitive adverse effects. Results: Treatment with nortriptyline enhanced the efficacy and reduced the cognitive adverse effects of ECT relative to placebo. Venlafaxine resulted in a weaker degree of improvement and tended to worsen cognitive adverse effects. High-dosage right unilateral ECT did not differ or was superior to bilateral ECT in efficacy and resulted in less severe amnesia. Conclusions: The efficacy of ECT is substantially increased by the addition of an antidepressant medication, but such medications may differ in whether they reduce or increase cognitive adverse effects. High-dose, right-sided, unilateral ECT is at least equivalent to moderate-dosage bilateral ECT in efficacy, but retains advantages with respect to cognitive adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=67650446544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650446544&partnerID=8YFLogxK

U2 - 10.1001/archgenpsychiatry.2009.75

DO - 10.1001/archgenpsychiatry.2009.75

M3 - Article

C2 - 19581564

AN - SCOPUS:67650446544

VL - 66

SP - 729

EP - 737

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 7

ER -